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Background
Exogenous stem cell therapy has shown benefits for treat-
ing peripheral arterial disease patients, who are not amen-
able for conventional revascularization therapy. Previously,
we have demonstrated the ability of imaging-visible cell
microencapsulation to overcome the challenges of poor
cell retention/survival and difficulties with monitoring cell
delivery success. However, in vivo cell viability cannot be
assessed noninvasively. Here, we investigate the potential
of PET-MRI tracking of 19F MRI-visible microencapsu-
lated human mesenchymal stem cells (hMSCs) labeled
with triple-fusion (TF) reporter gene in non-immunosup-
pressed rabbits.
Methods
Bone marrow-derived hMSCs were stably transfected
with a lentiviral vector encoding firefly luciferase, red
fluorescence protein, and thymidine kinase. Alginate cell
microencapsulation was performed using a modification
to incorporate perfluorooctylbromide (PFOB). Biolumi-
nescence imaging (BLI, Xenogen IVIS 2000) was
acquired before and after cell encapsulation to assess in
vitro cell viability. Rabbits received either intramuscular
injection of PFOB-encapsulated TF-hMSCs in the med-
ial thigh followed by intravenous administration of [18F]
9-[4-fluoro-3-(hydroxymethy) butyl] guanine ([18F]-
FHBG) (n=7, 1.7±0.7 mCi), or PFOB-encapsulated TF-
hMSCs that were pre-incubated with [18F]-FHBG (n=3,
55±2 µCi). Dynamic PET imaging (Siemens HRRT CPS
Innovation) was acquired immediately or 60 min after
transplantation for 30-90 min. Proton (3D GRE, TR/
TE=15/5.45 ms, FOV=186x230 mm, voxel size=0.45x
0.45x1.5mm) and 19F MRIs (TrueFISP, Siemens Tim
Trio, TR/TE=4.1/2.0 ms, 32 averages, FOV=250x250 mm,
image matrix=192x192, BW=1002 Hz/pixel, voxel size=
1.3x1.3x1.25 mm) were obtained 1-2 days after delivery.
PET images were fused with 1H/19F MR to identify the
location of transplanted cells. Follow-up PET imaging was
repeated within 1-14 days with intravenous or ultrasound-
guided intramuscular (0.7±0.3 mCi/thigh) of administra-
tion of [18F]-FHBG. Follow-up 19F MRIs were acquired
1-2 days after PET imaging. BLI was performed 2 weeks
after delivery.
Results
In vitro hMSC viability and transgene expression were not
affected by encapsulation or [18F]-FHBG incubation as
determined by BLI and live/dead cell staining (91±6%). All
PFOB cap injections were identified on 19F MRI in vivo
(Figure 1A). Using PET, PFOB microcapsule injection site
in rabbit thigh was identified as “hot spot” (Figure 1B)
and showed high concordance to the MRI “hot spot”
(Figure 1C). No significant volume change of PFOB Caps
was observed on 19F MRI over 2 weeks. BLI demonstrated
viable xenogeneic TF-hMSCs in PFOB microcapsules
2 week post delivery (Figure 1D).
Conclusions
We demonstrate xenogeneic MSC delivery in non-immu-
nosuppressed large animals using novel MRI-visible
microencapsulation and reporter gene labeling. PFOB
microencapsulation of TF-hMSCs enables cell tracking
and viability assessment using clinical PET-MRI.
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Figure 1 (A) 19F MR image of PFOB Caps containing TF-hMSCs in a the rabbit thigh; (B) PET image of PFOB Caps in the same rabbit; (C) Fusion of
19F MR image (blue) and PET image (red) with anatomical 1H MR showing the concordance “hot spot” and the location of PFOB Caps injection site;
(D) Bioluminescence imaging of the rabbit revealing highly viable encapsulated TF-hMSCs 2 weeks after delivery.
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